Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (0VQA.L) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Viking Therapeutics, Inc. (0VQA.L), covering cash flow, earnings, and balance sheets.
Viking Therapeutics, Inc. (0VQA.L) Income Statement & Financial Overview
Analyze Viking Therapeutics, Inc.’s 0VQA.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $87000.00 | $75000.00 |
| Gross Profit | $0.00 | $0.00 | -$87000.00 | -$75000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $41.39M | $30.99M | $22.79M | $23.77M |
| SG&A Expenses | $14.08M | $15.25M | $13.77M | $10.21M |
| Operating Expenses | $55.47M | $46.24M | $36.56M | $33.98M |
| Total Costs & Expenses | $0.00 | $46.24M | $36.56M | $34.05M |
| Interest Income | $0.00 | $10.84M | $11.53M | $11.82M |
| Interest Expense | $0.00 | $24000.00 | $24000.00 | $18000.00 |
| Depreciation & Amortization | $0.00 | $110000.00 | $87000.00 | $75000.00 |
| EBITDA | -$55.47M | -$46.13M | -$36.56M | -$34.05M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$55.47M | -$46.24M | -$36.56M | -$34.05M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $9.84M | $10.82M | $11.62M | $11.80M |
| Income Before Tax | -$45.63M | -$35.42M | -$24.94M | -$22.25M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$45.63M | -$35.42M | -$24.94M | -$22.25M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.41 | -$0.32 | -$0.22 | -$0.20 |
| Diluted EPS | -$0.41 | -$0.32 | -$0.22 | -$0.20 |
| Weighted Avg Shares Outstanding | $112.07M | $109.04M | $110.91M | $110.39M |
| Weighted Avg Shares Outstanding (Diluted) | $112.07M | $109.04M | $110.91M | $110.39M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$55.47M in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$55.47M. Net income dropped to -$45.63M, keeping EPS at -$0.41. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan